Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 4/20 | 0.45 |
| ▸ | HTR1A | P08908 | 3/20 | 0.45 |
| ▸ | DRD3 | P35462 | 2/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.43 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | DRD5 | P21918 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21351069 | 0.98 | HTR7 (0.44) | HTR7HTR1ADRD3HRH1HTR2B | |
| SCHEMBL24818999 | 0.98 | HTR7 (0.44) | HTR7HTR1ADRD3HRH1HTR2B | |
| SCHEMBL27283842 | 0.91 | GNAI3 (0.46) | DRD3GNAI3GNAO1GNAI1DRD2 | |
| SCHEMBL27281461 | 0.91 | GNAI3 (0.46) | DRD3GNAI3GNAO1GNAI1DRD2 | |
| SCHEMBL27281459 | 0.91 | GNAI3 (0.46) | DRD3GNAI3GNAO1GNAI1DRD2 | |
| SCHEMBL12513465 | 0.89 | GNAI3 (0.52) | GNAI3GNAO1GNAI1DRD2 | |
| SCHEMBL7738925 | 0.87 | GNAI3 (0.50) | GNAI3GNAO1GNAI1DRD2 | |
| SCHEMBL18526641 | 0.87 | GBA1 (0.39) | DRD3HRH3DRD2DRD1DRD4 | |
| SCHEMBL22318387 | 0.85 | SIGMAR1 (0.43) | DRD3HRH3GNAI3GNAO1GNAI1 | |
| SCHEMBL14877527 | 0.85 | GNAI3 (0.64) | HTR7HTR1ADRD3HRH1HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122854-A1 | Carbocyclic Fused Cyclic Amines | BOEHRINGER MARKUS (CH) | 2012-05-17 | — | — | US | disclosed |
| US-20070112012-A1 | Carbocyclic fused cyclic amines | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112012-A1 | Carbocyclic fused cyclic amines | F12, F11, F2 | HTR7 1128/4885HTR1A 413/4885DRD3 467/4885 |
| US-20120122854-A1 | Carbocyclic Fused Cyclic Amines | F12, F11, F2 | HTR7 1128/4885HTR1A 413/4885DRD3 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.